Icade focuses on healthcare real estate, shares steady in the French property sector

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 19:56.

Icade (FR0000035081) sits among France's listed property players with a focus on offices and healthcare assets around Paris and major regional cities. The shares trade on Euronext Paris, where liquidity has been muted recently compared with larger peers such as Unibail-Rodamco-Westfield and Gecina.

What the ownership structure shows

Icade highlights a significant public shareholder base with Caisse des Dépôts et Consignations as a key investor, underlining its semi-public profile in the French real estate landscape. The company details its capital structure and dividend history for shareholders on its investor relations pages, providing transparency on payouts and voting rights.

Analyst focus on the French property sector

Analysts covering French real estate typically compare Icade with listed office and retail landlords like Gecina and Unibail-Rodamco-Westfield when looking at leverage, occupancy and yields, according to sector commentary in the Paris market. In that context, Icade's tilt toward healthcare real estate is seen as a defensive angle in an environment of higher interest rates and cautious investor sentiment.

How Icade makes its money

Icade generates rental income from a portfolio of office buildings, business parks and healthcare facilities, primarily in France. The company also engages in property development, selling completed residential and commercial projects, which adds fee and margin income alongside recurring rent.

Where the stock trades today

The Icade shares (FR0000035081) are listed on Euronext Paris; recent data on live.deutsche-boerse.com show no active quote on German venues, underlining the stock's primary trading on its home market. The latest available reference price on Deutsche Börse systems is 0.00 euros, reflecting the absence of recent trading activity rather than an economic valuation.

Disclaimer: This article provides factual information on the Icade shares and does not contain investment advice, buy or sell recommendations or price targets. Data are based on publicly available sources believed to be reliable at the time of publication.